Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 4c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $38.82 million versus the consensus estimate of $44.5 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c